An FDA advisory committee will meet at month's end to evaluate Promacta, GlaxoSmithKline's drug candidate for treating a disorder in which blood does not clot properly, according to Amgen. Both companies are seeking approval for drugs that treat the condition. Glaxo could not be reached for comment.

Full Story:

Related Summaries